Account
Inquiry
XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for research purposes. This synthetic peptide demonstrates significant potential in metabolic disorder studies through its unique mechanism of action.
The compound works by simultaneously targeting both GIP and GLP-1 receptors, which may enhance insulin secretion while suppressing glucagon release in a glucose-dependent manner. Research suggests this dual agonism could offer advantages in glycemic control and weight management studies.
Our XCE Tirzepatide is synthesized under strict quality control measures, with comprehensive analytical testing including HPLC and MS verification. The product is provided as lyophilized powder in sterile vials with batch-specific certificates of analysis.
Important Note: This product is intended for laboratory research use only. Not for human consumption or diagnostic use. Proper handling procedures should be followed by qualified researchers.
